Pharmafile Logo
Pharmafocus logo
Advanced Search

Shire

Showing 15 posts of 170 posts found.

jon_neal-1_0

Takeda announces new UK MD, ahead of Shire transformation

May 1, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Shire, Takeda, appointment, pharma

“Jon’s appointment comes at an exciting time for the company” reads the company press on annoucing its new Managing Director …

Appointment
4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

April 27, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Eli Lilly, FDA, Fresenius, Shire, Takeda, arthritis, pharma

The year seems like it’s running away as we come to the end of April. It’s been a more tense …

News

Takeda announce new UK MD, ahead of possible Shire transformation

April 26, 2018
Medical Communications Shire, Takeda, biotech, drugs, pharma, pharmaceutical

“Jon’s appointment comes at an exciting time for the company” reads the company press on annoucing its new Managing Director …

News
china_block_001_takeda

$64bn Takeda-Shire mega merger inches closer to closing

April 25, 2018
Research and Development, Sales and Marketing Shire, Takeda, biotech, drugs, pharma, pharmaceutical

From March onwards, Takeda has been nudging a deal with Shire onwards through repeatedly improved offers, which has seen the …

News
pharmafocus_may_2018_cover

The May 2018 issue of Pharmafocus is now live!

April 23, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BMS, MSD, Pharmafocus, Shire, Takeda, flypharma, keytruda, mhealth, mobile health summit, opdivo, pharma, sugar tax

Just in time for the first good weather of the year, the May 2018 edition of Pharmafocus is available to …

News
top_ten

Top Ten most popular articles on Pharmafile.com this week

April 20, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Amgen, EMA, GW Pharma, J&J, JJ, MHRA, Mylan, Novartis, Sanofi, Shire, Takeda, biotech, drugs, epipen, keytruda, pharma, pharmaceutical

It’s the end of another week and there’s really been one story that has dominated the headlines – Takeda’s potential …

News

Allergan out but Takeda sticks to guns on Shire

April 20, 2018
Medical Communications, Sales and Marketing Allergan, Shire, Takeda, biotech, drugs, pharma, pharmaceutical

Allergan performed an odd about-turn after initially declaring its interest in pursuing a deal for Shire, before reneging on that …

News
shire_image

Shire jettisons oncology unit for $2.4bn, unbalancing Takeda deal

April 16, 2018
Sales and Marketing Servier, Shire, Takeda, biotech, drugs, oncology, pharma, pharmaceutical

Shire has announced that it has entered a definitive agreement for French drugmaker Servier to take on its oncology business. …

News
4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

April 13, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AbbVie, Cancer, Humira, Mylan, Novartis, Shire, Takeda, Teva, acquisition, cystic fibrosis, hepatitis C, pharma, top ten

It’s Friday the 13th, but that doesn’t change a strong showing from the industry this week as it continued to …

News
china_block_001_takeda

Takeda move for Shire looks increasingly likely

April 6, 2018
Medical Communications, Sales and Marketing Japan, Shire, Takeda, UK, biotech, drugs, pharma, pharmaceutical

Takeda’s surprise announcement, just last week, that it was weighing up a move for Shire had some analysts sceptical about …

News
shire_image

Takeda moots Shire move but big questions remain

March 28, 2018
Sales and Marketing Shire, Takeda, biotech, drugs, pharma, pharmaceutical

Takeda is considering making a bold move for Shire, after announcing, as per UK regulations, that it may make an …

News
4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

February 23, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AbbVie, Alzheimer's, AstraZeneca, Eylea, FDA, Microsoft, Regeneron, Shire, Tremfya, eurordis, multiple myeloma, rare disease

It’s the last Friday of February, and it’s time for another run-down of the most popular stories of the week. …

News
business_generic

Shire, Microsoft and EURORDIS form rare disease alliance

February 20, 2018
Manufacturing and Production, Research and Development Microsoft, Shire, eurordis, pharma, rare disease

Rare disease specialist pharma firm Shire, rare disease patient alliance EURORDIS and tech giant Microsoft have announced they have formed …

News
shire_image_4

Shire scores European approval for Adynovi in haemophilia A

January 15, 2018
Sales and Marketing Adynovi, Europe, European Commission, Shire, haemophilia, haemophilia a, pharma

Shire has revealed that the European Commission has approved Adynovi (antihaemophilic factor (recombinant), PEGylated) for on-demand and prophylactic use in …

News
4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

January 12, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bayer, HIV, J&J, JJ, Johnson & Johnson, Pfizer, Shire, Teva, Xarelto, patient reported outcomes

The Xmas break is now a distant memory as we move further into January, and with another Friday comes another …

News
The Gateway to Local Adoption Series

Latest content

Siemens Healthineers opens 10m euro R&D centre for laboratory equipment in Ireland

February 19, 2026

Everdrone announces new board of directors to drive expansion

February 19, 2026

Regeneron announces presentations of new data on Eylea HD for retinal disease

February 18, 2026

Indegene completes acquisition of Cake Health

February 18, 2026

Gedeon Richter UK acquires rights to schizophrenia treatment Reagila from Recordati Pharmaceuticals

February 17, 2026